Role fluorodeoxglucose (FDG)-positron emission tomography imaging for Hodgkin and Diffuse Large B-Cell Lymphoma | ||||
| Minia Journal of Medical Research | ||||
| Volume 31, Issue 4, October 2020, Page 92-94 PDF (129.55 K) | ||||
| Document Type: Original Article | ||||
| DOI: 10.21608/mjmr.2022.217130 | ||||
 View on SCiNiTO | ||||
| Authors | ||||
| Asmaa H. Fathy; Mai Khalifa | ||||
| Department of Clinical Oncology and Nuclear Medicine, Faculty of Medicine and Sohag University | ||||
| Abstract | ||||
| The use of 18F-fluorodeoxyglucose (FDG)-positron emission tomography (PET) in conjunction with computed tomography has recently become important in the initial staging, evaluation of response, and treatment of malignant lymphomas. PET has shown high sensitivity in early and late response assessment during treatment, and early diagnosis of lymphoma manifestations. PET is most helpful in evaluating how well DLBCL and Hodgkin's lymphoma patients are responding to treatment. PET- CT in staging is extremely sensitive at identifying lymphoma lesions, and it is used to help doctors decide on treatment options, resulting in better therapy selection this imaging technique is often used to assess individual chemo sensitivity and adjust treatment accordingly. FDG-PET may also be used to assess residual masses after treatment is over. Patients with a negative FDG-PET scan should be considered in full remission, according to a recent update. FDG-PET/CT is no longer used in routine follow-up following a full metabolic response to treatment, but it is still a useful tool for excluding recurrence if patients experience clinical symptom suggestive of disease relapse. | ||||
| Keywords | ||||
| Hodgkin lymphoma; diffuse large B-cell lymphoma; positron emission tomography; staging; response assessment; treatments | ||||
|
Statistics Article View: 79 PDF Download: 209 |
||||
